Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 14/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613700 | 0.91 | TRPV1 (0.59) | TRPV1NPY5RMCHR1 | |
| SCHEMBL13613656 | 0.91 | TRPV1 (0.62) | TRPV1NPY5RMEN1LMNAMAPT | |
| SCHEMBL13613655 | 0.91 | TRPV1 (0.56) | TRPV1NPY5RMCHR1MEN1LMNA | |
| SCHEMBL14278360 | 0.90 | TRPV1 (0.56) | TRPV1NPY5RMEN1LMNAMAPT | |
| SCHEMBL4336612 | 0.90 | TRPV1 (0.64) | TRPV1 | |
| SCHEMBL13613591 | 0.88 | TRPV1 (0.59) | TRPV1MEN1MAPTKMT2A | |
| SCHEMBL13613710 | 0.85 | TRPV1 (0.64) | TRPV1 | |
| SCHEMBL13613705 | 0.85 | TRPV1 (0.56) | TRPV1MEN1MAPTKMT2A | |
| SCHEMBL4332016 | 0.85 | TRPV1 (0.64) | TRPV1EPHX1 | |
| SCHEMBL13613697 | 0.84 | TRPV1 (0.62) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612113-B2 | Such as N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, COPD | XENTION LIMITED (GB) | 2009-11-03 | — | — | US | claimed |
| EP-1506167-B1 | HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-08-29 | — | — | EP | claimed |
| US-20060258742-A1 | Hydroxy tetrahydro-naphthalenylurea derivatives | BAYER HEAITHCARE AG (DE) | 2006-11-16 | — | — | US | claimed |
| EP-1506167-A1 | HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | Bayer HealthCare AG (DE) | 2005-02-16 | — | — | EP | claimed |
| WO-2003095420-A1 | HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-11-20 | — | — | WO | claimed |
| US-7612113-B2 | Such as N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, COPD | XENTION LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612113-B2 | Such as N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, COPD | XENTION LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612113-B2 | Such as N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, COPD | XENTION LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| EP-1506167-B1 | HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-08-29 | — | — | EP | disclosed |
| US-20060258742-A1 | Hydroxy tetrahydro-naphthalenylurea derivatives | BAYER HEAITHCARE AG (DE) | 2006-11-16 | — | — | US | disclosed |
| EP-1506167-A1 | HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | Bayer HealthCare AG (DE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003095420-A1 | HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258742-A1 | Hydroxy tetrahydro-naphthalenylurea derivatives | NMUR1, HVCN1, GPR17 | TRPV1 18/4885NPY5R 3549/4885MCHR1 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.